Markets: Down
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.NYCOMED AMERSHAM, the diagnostic equipment maker, fell 6.9 per cent last week on concern over US competition, especially in the market for imaging supplies, where the company now generates nearly half of sales. "There's pricing pressure in various markets," said Nigel Barnes, pharmaceuticals analyst with Merrill Lynch.
Daiwa Europe analyst Nigel Keegan said some investors are concerned that Nycomed's new imaging agent, NC100100, may face higher-than-expected competition when it hits the market in 2001. Sonus and Molecular Biosystems are emerging as likely rivals.
"Nycomed gave the impression that NC100100 would own the market, but there are others already there," he said.
Copyright: IOS & Bloomberg
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments